Introduction Sickle cell disease (SCD) in pregnancy has been associated with adverse pregnancy outcomes. However, with a multidisciplinary approach and surveillance, there is a suggestion of improvement in the overall outcome. The aim of this study was to evaluate the pregnancy outcomes in women with known SCD in a singleton pregnancy seen in our clinic, and to assess whether the presence of SCD alters the maternal serum analytes (Free B-human chorionic gonadotrophin and Pregnancy-associated plasma protein - A) at combined screening.

Methods Case-control study of all pregnant women with SCD undergoing combined screening from 01/01/2008 to 31/12/2011. Each case was matched with 3 non-SCD controls. Pregnancy outcomes in the two groups were compared.

Conclusion Women with SCD, when followed closely from the first trimester, have successful pregnancy outcomes. However, our data suggests an increased incidence of pre-eclampsia and lower birth weights compared to non-SCD controls. There was also a significant difference noted in the maternal serum analytes. Larger prospective studies are therefore required to assess the impact of SCD on combined screening.